<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chagas disease: Antitrypanosomal drug therapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chagas disease: Antitrypanosomal drug therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chagas disease: Antitrypanosomal drug therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Caryn Bern, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1635514329"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Chagas disease is caused by infection with the protozoan parasite <em>Trypanosoma cruzi </em>[<a href="#rid1">1</a>]. Issues related to antitrypanosomal drugs will be reviewed here.</p><p>The approach to management of Chagas disease varies by phase and form of disease and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a> and  <a class="medical medical_review" href="/d/html/114192.html" rel="external">"Chagas disease: Chronic Trypanosoma cruzi infection"</a>.)</p><p class="headingAnchor" id="H2757853556"><span class="h1">ANTITRYPANOSOMAL DRUGS</span><span class="headingEndMark"> — </span>The only drugs with proven efficacy against Chagas disease in human trials are <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">benznidazole</a> and <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">nifurtimox</a> [<a href="#rid2">2-4</a>]. In general, benznidazole is better tolerated and so is favored by most experts as the first-line treatment for Chagas disease [<a href="#rid5">5</a>]. In addition, compared with nifurtimox, there are more recent clinical trial data for the use of benznidazole, which was used in both pediatric trials in the 1990s [<a href="#rid6">6,7</a>] and in several drug trials [<a href="#rid8">8-10</a>]. However, some patients tolerate nifurtimox better than benznidazole; when treatment with one drug must be discontinued, the other can be used as an alternative. Limited human data, supported by findings in animal models, suggest that <em>T. cruzi</em> strains may vary in their drug susceptibility [<a href="#rid11">11-14</a>].</p><p>Both <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">benznidazole</a> and <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">nifurtimox</a> are contraindicated in pregnancy, so effective contraception should be assured. In addition, both drugs demonstrate in vitro mutagenicity and have been associated with increased risk of lymphomas in experimental animals [<a href="#rid15">15-18</a>]. No increase in incidence of lymphoma has been observed among immunocompetent humans, although no long-term studies examining this issue have been conducted [<a href="#rid19">19</a>]. An increased incidence of neoplasm was reported in a small series of heart transplantation recipients for Chagas disease [<a href="#rid20">20</a>].</p><p>Antitrypanosomal agents are contraindicated in patients with severe renal or hepatic dysfunction.</p><p><a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">Benznidazole</a> was approved by the US Food and Drug Administration (FDA) in August 2017 and became commercially available in the United States in May 2018. The FDA approval is for treatment of Chagas disease in children ages 2 to 12 years [<a href="#rid21">21</a>]; use for other age groups is off-label. Prescriptions require submission of a completed order form, available at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.benznidazoletablets.com%2F&amp;token=GeFV9Vdjd1QA9C8FF7DBCeM0eBCzH8xMreHDqQKcZfT7H9zOwy3LW%2B4TGQwqrC7P&amp;TOPIC_ID=14004" target="_blank">http://www.benznidazoletablets.com/</a> or by contacting Foundation Care (tel 877-303-7181; fax 877-620-2849; email <a class="__cf_email__" data-cfemail="397f584a4d785a5a5c4a4a797c415c554d504a175a5654" href="/cdn-cgi/l/email-protection">[email protected]</a>). Urgent requests for benznidazole should be made by telephone.</p><p><a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">Nifurtimox</a> was approved by the FDA in August 2020 for treatment of Chagas disease in children up to 17 years of age [<a href="#rid22">22</a>]; use for other age groups is off-label. The approved dosing schedule differs from the dosing schedule approved under the United States Centers for Disease Control and Prevention (CDC) investigational protocol (which has been in place for the last 30 years) with lower daily dosing and a shorter course (<a class="graphic graphic_table graphicRef54443" href="/d/graphic/54443.html" rel="external">table 1</a>) [<a href="#rid23">23</a>]. As of January 2021, nifurtimox is available from Bayer distribution centers through commercial pharmacy requests.</p><p>The CDC provides diagnostic and clinical consultations via the Division of Parasitic Diseases Public Inquiries line (404-718-4745; email <a class="__cf_email__" data-cfemail="dbabbaa9baa8b2afbea89bb8bfb8f5bcb4ad" href="/cdn-cgi/l/email-protection">[email protected]</a>) and for emergencies after business hours, on weekends, and on federal holidays, through the CDC Emergency Operations Center (770-488-7100).</p><p class="headingAnchor" id="H2891213335"><span class="h2">Benznidazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">Benznidazole</a> is a nitroimidazole derivative with activity against <em>T. cruzi</em> trypomastigotes and amastigotes; it was introduced in 1971. The drug is rapidly absorbed from the gastrointestinal tract, and the average half-life is 12 hours. Elimination is predominantly renal; about 22 percent of excretion is fecal. The weight-corrected clearance rate (CL/F) is significantly higher, and the same dosing regimen leads to lower plasma levels in younger than older children and adults [<a href="#rid24">24</a>].</p><p>Dosing is outlined in the table (<a class="graphic graphic_table graphicRef54443" href="/d/graphic/54443.html" rel="external">table 1</a>). The duration of therapy is usually 60 days. A phase II trial suggests that a course as short as two weeks may have similar efficacy but changes in recommended regimens will require additional data [<a href="#rid10">10</a>]. Children have fewer side effects than adults and tolerate higher doses. Laboratory testing, including complete blood count (CBC), hepatic enzymes, bilirubin, serum creatinine, and blood urea nitrogen, should be performed before beginning treatment, and the CBC should be repeated every 2 to 3 weeks during treatment.</p><p>Adverse effects include dermatitis, peripheral neuropathy, angioedema, and bone marrow suppression [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Dermatologic side effects are frequent and consist of rash due to photosensitization with rare progression to exfoliative dermatitis (<a class="graphic graphic_table graphicRef67193" href="/d/graphic/67193.html" rel="external">table 2</a>) [<a href="#rid26">26,27</a>]. The dermatitis reflects a delayed hypersensitivity reaction and is usually manageable with topical or low-dose systemic corticosteroids. Severe dermatitis, exfoliative dermatitis, or dermatitis associated with fever and lymphadenopathy should prompt immediate cessation of the drug. Patients should be monitored weekly for dermatologic side effects beginning about 10 days after initiation of treatment. In one cohort study, the median onset of dermatitis was in the second week of treatment, but nearly 20 percent had onset at four weeks or later [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy is dose dependent and usually occurs after four weeks or more of therapy [<a href="#rid28">28</a>]. Onset of peripheral neuropathy should prompt immediate cessation of treatment. It is nearly always reversible but may take months to resolve.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow suppression is rare; it should prompt immediate interruption of drug treatment. Blood counts should be monitored every two to three weeks during the treatment.</p><p></p><p>Concurrent alcohol use can lead to disulfiram-like effects (abdominal cramps, nausea, vomiting, flushing, or headache) and should be avoided [<a href="#rid29">29</a>].</p><p>Evidence for efficacy of <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">benznidazole</a> and the approach to its use varies by phase and form of disease. (See  <a class="medical medical_review" href="/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a> and  <a class="medical medical_review" href="/d/html/114192.html" rel="external">"Chagas disease: Chronic Trypanosoma cruzi infection"</a>.)</p><p class="headingAnchor" id="H1023673722"><span class="h2">Nifurtimox</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">Nifurtimox</a> is a nitrofuran compound with activity against <em>T. cruzi</em> trypomastigotes and amastigotes; it was introduced in 1965 [<a href="#rid2">2,30,31</a>]. The drug is rapidly absorbed from the gastrointestinal tract and metabolized in the liver, where nitroreduction occurs through the cytochrome P450 reductase. Elimination of metabolites is predominantly renal. After a single oral dose in humans, plasma levels peak at one hour and have an elimination half-life of three hours.</p><p>Dosing is outlined in the table (<a class="graphic graphic_table graphicRef54443" href="/d/graphic/54443.html" rel="external">table 1</a>). Historically, the duration of therapy was usually at least 90 days [<a href="#rid32">32</a>], but recommendations have decreased the recommended regimen to 60 days [<a href="#rid33">33,34</a>]. <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">Nifurtimox</a> is better tolerated by children than adults [<a href="#rid32">32,35,36</a>]; the approach to dosing depends on patient age.</p><p>Adverse effects are frequent but usually resolve when treatment is discontinued (<a class="graphic graphic_table graphicRef67193" href="/d/graphic/67193.html" rel="external">table 2</a>). They include gastrointestinal complaints and central nervous system toxicity [<a href="#rid32">32</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal complaints occur in 30 to 70 percent of patients and include anorexia leading to weight loss, nausea, vomiting, and abdominal discomfort [<a href="#rid32">32,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system toxicity is also common, including irritability, insomnia, and disorientation. Less common side effects include tremors, paresthesias, polyneuropathy, and peripheral neuropathy. Peripheral neuropathy is dose dependent, appears late in the course of therapy, and should prompt interruption of treatment.</p><p></p><p>Laboratory testing (CBC, hepatic enzymes, bilirubin, serum creatinine, and blood urea nitrogen) should be performed before beginning treatment, every four to six weeks during the course, and at the end of treatment. Patients should be weighed and monitored for symptoms and signs of peripheral neuropathy every two weeks, especially during the second and third months of treatment.</p><p>Alcohol use may increase the risk of side effects and should be avoided during <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">nifurtimox</a> treatment [<a href="#rid38">38</a>].</p><p>Evidence for efficacy of <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">nifurtimox</a> and the approach to its use varies by phase and form of disease. (See  <a class="medical medical_review" href="/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a> and  <a class="medical medical_review" href="/d/html/114192.html" rel="external">"Chagas disease: Chronic Trypanosoma cruzi infection"</a>.)</p><p class="headingAnchor" id="H1776904667"><span class="h1">NEW DRUGS</span><span class="headingEndMark"> — </span>New, more effective drugs with fewer side effects are needed, although progress in developing and testing drug candidates has been slow [<a href="#rid39">39</a>].</p><p>Triazoles that inhibit ergosterol synthesis, including <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> and ravuconazole, have in vitro activity against <em>T. cruzi</em> [<a href="#rid40">40,41</a>]. However, thus far posaconazole does not appear to be effective for clinical treatment of Chagas disease:</p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial including 120 asymptomatic <em>T. cruzi–</em>infected adults compared the combination of <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> and <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">benznidazole</a> with posaconazole monotherapy, benznidazole monotherapy, and placebo [<a href="#rid9">9</a>]. Treatment failure (defined by positive results by quantitative polymerase chain reaction (PCR) during six months of follow-up) was observed among 13 percent of patients who received benznidazole monotherapy, 20 percent of patients who received posaconazole plus benznidazole, 86 percent of patients who received posaconazole monotherapy, and 90 percent of patients who received placebo. There was no statistically significant difference in efficacy between benznidazole monotherapy and the combination of benznidazole plus posaconazole; however, the trial was inadequately powered to detect such a difference. Among patients who received benznidazole, 32 percent discontinued early due to adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 78 adults with chronic <em>T. cruzi</em> infection, treatment failure occurred among most patients who received <a class="drug drug_general" data-topicid="9479" href="/d/drug information/9479.html" rel="external">posaconazole</a> (80 percent in the high-dose arm; 90 percent in the low-dose arm), compared with 6 percent of patients who completed the 60-day course of <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">benznidazole</a> (per protocol analysis) [<a href="#rid8">8</a>]. In the intention-to-treat analysis, the failure rate in the benznidazole arm was 38 percent.</p><p></p><p>Other drug candidates with in vitro (and in some cases in vivo) activity include other nitroimidazoles (eg, <a class="drug drug_general" data-topicid="132112" href="/d/drug information/132112.html" rel="external">fexinidazole</a>), cruzipain inhibitors, bisphosphonates, and trypanothione synthesis inhibitors [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H3234180781"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113058.html" rel="external">"Society guideline links: Chagas disease"</a>.)</p><p class="headingAnchor" id="H3724774322"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach </strong>–<strong> </strong>The approach to management of Chagas disease varies by phase and form of disease and is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/114181.html" rel="external">"Chagas disease: Acute and congenital Trypanosoma cruzi infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drugs</strong> – <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">Benznidazole</a> and <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">nifurtimox</a> are the only drugs with proven efficacy against Chagas disease in humans. In general, we favor benznidazole as first-line treatment for Chagas disease, since in general it is better tolerated than nifurtimox and there are more recent efficacy data available of benznidazole. (See <a class="local">'Antitrypanosomal drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Dosing and duration for <a class="drug drug_general" data-topicid="114673" href="/d/drug information/114673.html" rel="external">benznidazole</a> and <a class="drug drug_general" data-topicid="126252" href="/d/drug information/126252.html" rel="external">nifurtimox</a> are outlined in the table (<a class="graphic graphic_table graphicRef54443" href="/d/graphic/54443.html" rel="external">table 1</a>). Adverse effects are outlined in the table (<a class="graphic graphic_table graphicRef67193" href="/d/graphic/67193.html" rel="external">table 2</a>). (See <a class="local">'Benznidazole'</a> above and <a class="local">'Nifurtimox'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bern C, Messenger LA, Whitman JD, Maguire JH. Chagas Disease in the United States: a Public Health Approach. Clin Microbiol Rev 2019; 33.</a></li><li><a class="nounderline abstract_t">Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97:3.</a></li><li class="breakAll">Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.</li><li class="breakAll">Pan American Health Organization. Guidelines for the diagnosis and treatment of Chagas disease. Washington, D.C.: PAHO; 2019. http://iris.paho.org/xmlui/bitstream/handle/123456789/49653/9789275120439_eng.pdf?sequence=6&amp;isAllowed=y (Accessed on July 08, 2019).</li><li><a class="nounderline abstract_t">Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.</a></li><li><a class="nounderline abstract_t">de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.</a></li><li><a class="nounderline abstract_t">Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526.</a></li><li><a class="nounderline abstract_t">Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.</a></li><li><a class="nounderline abstract_t">Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol 2017; 69:939.</a></li><li><a class="nounderline abstract_t">Torrico F, Gascón J, Barreira F, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis 2021; 21:1129.</a></li><li><a class="nounderline abstract_t">Boainain E. Tratamento etiologico da doença de Chagas na fase cro. Rev Goiania Med 1979; 25:1.</a></li><li><a class="nounderline abstract_t">Camandaroba EL, Reis EA, Gonçalves MS, et al. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 2003; 36:201.</a></li><li><a class="nounderline abstract_t">Veloso VM, Carneiro CM, Toledo MJ, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 2001; 96:1005.</a></li><li><a class="nounderline abstract_t">Zingales B, Miles MA, Moraes CB, et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz 2014; 109:828.</a></li><li><a class="nounderline abstract_t">Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res 1986; 19:19.</a></li><li><a class="nounderline abstract_t">Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat Res 1989; 224:263.</a></li><li><a class="nounderline abstract_t">Teixeira AR, Córdoba JC, Souto Maior I, Solórzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg 1990; 43:146.</a></li><li><a class="nounderline abstract_t">Teixeira AR, Silva R, Cunha Neto E, et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes. J Comp Pathol 1990; 103:37.</a></li><li><a class="nounderline abstract_t">Kirchhoff LV. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 1993; 7:487.</a></li><li><a class="nounderline abstract_t">Bocchi EA, Higuchi ML, Vieira ML, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant 1998; 17:399.</a></li><li class="breakAll">Drugs for Neglected Diseases Initiative. Press releases: U.S. FDA approves Chemo Group’s benznidazole to treat children with Chagas disease. https://www.dndi.org/2017/media-centre/press-releases/fda-approves-benznidazole-chagas-children/ (Accessed on September 06, 2017).</li><li class="breakAll">US Food and Drug Administration. New Drug Application (NDA): 213464. Nifurtimox (Lampit). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=213464 (Accessed on August 21, 2020).</li><li class="breakAll">Nifurtimox [package insert]. Whippany, NJ: Bayer; 2020.</li><li><a class="nounderline abstract_t">Altcheh J, Moscatelli G, Mastrantonio G, et al. Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults. PLoS Negl Trop Dis 2014; 8:e2907.</a></li><li><a class="nounderline abstract_t">Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.</a></li><li><a class="nounderline abstract_t">Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010; 54:4896.</a></li><li><a class="nounderline abstract_t">Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis 2015; 61:1688.</a></li><li><a class="nounderline abstract_t">Tornheim JA, Lozano Beltran DF, Gilman RH, et al. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis 2013; 7:e2407.</a></li><li class="breakAll">US Pharmacopeial Convention. Benznidazole, Convention UP (Ed), US Pharmacopeia Monographs, 1995.</li><li><a class="nounderline abstract_t">Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.</a></li><li><a class="nounderline abstract_t">Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624.</a></li><li><a class="nounderline abstract_t">Forsyth CJ, Hernandez S, Olmedo W, et al. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States. Clin Infect Dis 2016; 63:1056.</a></li><li><a class="nounderline abstract_t">Altcheh J, Castro L, Dib JC, et al. Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO). PLoS Negl Trop Dis 2021; 15:e0008912.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Chagas disease: Antiparasitic treatment. https://www.cdc.gov/parasites/chagas/health_professionals/tx.html (Accessed on September 06, 2017).</li><li><a class="nounderline abstract_t">Berenstein AJ, Falk N, Moscatelli G, et al. Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults. Antimicrob Agents Chemother 2021; 65.</a></li><li><a class="nounderline abstract_t">Abbott A, Montgomery SP, Chancey RJ. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021. MMWR Morb Mortal Wkly Rep 2022; 71:371.</a></li><li><a class="nounderline abstract_t">Jackson Y, Alirol E, Getaz L, et al. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin Infect Dis 2010; 51:e69.</a></li><li class="breakAll">US Pharmacopeial Convention. Nifurtimox, Convention UP (Ed), US Pharmacopeia Monographs, 1995.</li><li><a class="nounderline abstract_t">Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&amp;D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484.</a></li><li><a class="nounderline abstract_t">Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979.</a></li><li><a class="nounderline abstract_t">Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55.</a></li><li><a class="nounderline abstract_t">Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis 2009; 49:1685.</a></li><li><a class="nounderline abstract_t">Bahia MT, Diniz Lde F, Mosqueira VC. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opin Investig Drugs 2014; 23:1225.</a></li></ol></div><div id="topicVersionRevision">Topic 14004 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31776135" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chagas Disease in the United States: a Public Health Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992141" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A critical review on Chagas disease chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992141" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A critical review on Chagas disease chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992141" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A critical review on Chagas disease chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26222561" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chagas' Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937280" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790423" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24827034" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28231946" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33836161" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tratamento etiologico da doença de Chagas na fase cro</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12806455" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11685270" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25317712" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3542090" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2507913" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2117856" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chagas' disease: lymphoma growth in rabbits treated with Benznidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2203830" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8254156" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Chagas disease. American trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588585" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588585" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588585" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9588585" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853169" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Population pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714649" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antitrypanosomal therapy for chronic Chagas' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823286" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Tolerance of benznidazole in treatment of Chagas' disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26265500" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069472" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069472" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4630486" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Experience with nifurtimox in chronic Chagas' infection. Preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4630485" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of nifurtimox in acute Chagas' infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27432838" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33412557" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33412557" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33168612" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35271563" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20932171" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tolerance and safety of nifurtimox in patients with chronic chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20932171" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Tolerance and safety of nifurtimox in patients with chronic chagas disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19582163" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : New, improved treatments for Chagas disease: from the R&amp;D pipeline to the patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404124" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19900395" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877968" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : New advances in the management of a long-neglected disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855989" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Therapeutical approaches under investigation for treatment of Chagas disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
